Xenon Pharmaceuticals Reports Q3 2026 Financial Results and Azetukalner FDA Submission
Xenon Pharmaceuticals reported its third-quarter 2026 financial results, highlighting a net loss of $110.4 million compared to $90.9 million in the prior year. Despite the increased loss, driven by higher R&D spending for Phase 3 studies and manufacturing preparations, the company maintains a strong liquidity position with $1.2 billion in cash and marketable securities, which management expects will fund operations through 2029. A key milestone was reached with the September 2026 New Drug Application (NDA) submission to the FDA for azetukalner to treat focal seizures. The company also provided updates on its pipeline, including X-NOVA2 enrollment for major depressive disorder and Phase 1 data for XEN1701 showing high receptor occupancy. However, management noted a voluntary pause in new patient enrollment due to neuropsychiatric adverse events observed during the MDD study.
Topics: clinical trials earnings report FDA submission financial results